Financial Tearsheet

Company Overview

Recent Financial News

Date   Headline
Mar 25, 2020 Aytu BioScience Regains Compliance with NASDAQ Minimum Bid Price Requirement
Mar 23, 2020 Aytu BioScience Submits Notice of Commercialization to the FDA, Allowing for Company's Distribution of its 2-10 Minute COVID-19 IgG/IgM Point-of-Care Rapid Test
Mar 19, 2020 Aytu Announces $20 Million Registered Direct Offering Priced At-the-Market
Mar 19, 2020 Aytu BioScience Expands Its Distribution Rights for Coronavirus 2019 (COVID-19) Point-of-Care Rapid Test to Canada and Mexico
Mar 17, 2020 Aytu BioScience Announces Acceleration of U.S. Availability of COVID-19 IgG/IgM Rapid Test Based on Updated FDA Policy

IR Contacts

Hayden IR

James Carbonara
1441 Broadway
Fifth Floor
New York, NY 10018
Office: (646)-755-7412
James@haydenir.com

Stock Performance

Today's Open 1.70
Volume 26.08 million
Day Range 1.66 - 1.86
52 Week Range 0.34 - 2.99
Bid/Ask 1.81 / 1.81
Bid/Ask Size 91,600 X 32,200
Previous Close 1.60
Market Cap 37.73 million
Shares Outstanding 20.73 million
Dividend/Yield 0.00 / 0.00%
EPS (TTM) -1.658600
P/E Ratio (TTM) N/A

Recent XBRL Filings

Filing Date Form Type Description View
Feb 14, 2020 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
Nov 14, 2019 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
Sep 26, 2019 10-K Annual report htmlhtml   pdfpdf   xbrlxbrl  
May 14, 2019 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
May 14, 2019 10-Q/A Quarterly report (Amendment) htmlhtml   pdfpdf   xbrlxbrl  

Management Team

Josh Disbrow, Chairman & Chief Executive Officer

Jarrett Disbrow, Chief Operating Officer

David Green, Chief Financial Officer

Board of Directors

Josh Disbrow, Chairman & Chief Executive Officer

Gary Cantrell, Director, Chair, Compensation Committee

Carl Dockery, Director, Chair, Nominating & Governance Committee

John Donofrio, Jr., Director, Chair, Audit Committee

Michael Macaluso, Director